Armata Pharmaceuticals, Inc. (ARMP)
USD 1.95
(-2.5%)
USD 1.95
(-2.5%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 11.64 Million USD | -68.47% |
| 2022 | 36.94 Million USD | 55.09% |
| 2021 | 23.82 Million USD | 10.35% |
| 2020 | 21.58 Million USD | 13.09% |
| 2019 | 19.08 Million USD | 80.19% |
| 2018 | 10.59 Million USD | 1.17% |
| 2017 | 10.47 Million USD | -25.69% |
| 2016 | 14.09 Million USD | 31.67% |
| 2015 | 10.7 Million USD | -26.29% |
| 2014 | 14.51 Million USD | -5.17% |
| 2013 | 15.31 Million USD | 226.6% |
| 2012 | 4.68 Million USD | 0.0% |
| 2008 | 21 Million USD | -15.09% |
| 2007 | 24.73 Million USD | -44.52% |
| 2006 | 44.58 Million USD | 81.9% |
| 2005 | 24.51 Million USD | 2.4% |
| 2004 | 23.93 Million USD | 5.51% |
| 2003 | 22.68 Million USD | -42.92% |
| 2002 | 39.74 Million USD | -16.29% |
| 2001 | 47.48 Million USD | 66.73% |
| 2000 | 28.47 Million USD | 46.05% |
| 1999 | 19.5 Million USD | 8.94% |
| 1998 | 17.9 Million USD | 2.87% |
| 1997 | 17.4 Million USD | 6.75% |
| 1996 | 16.3 Million USD | 36.97% |
| 1995 | 11.9 Million USD | 19.0% |
| 1994 | 10 Million USD | 69.49% |
| 1993 | 5.9 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.87 Million USD | 0.58% |
| 2024 Q2 | 11.59 Million USD | 9.53% |
| 2023 FY | 44.44 Million USD | 20.3% |
| 2023 Q1 | 11.34 Million USD | 9.85% |
| 2023 Q2 | 9.62 Million USD | -15.13% |
| 2023 Q4 | 10.81 Million USD | 4.62% |
| 2023 Q3 | 10.33 Million USD | 7.34% |
| 2022 Q2 | 9.22 Million USD | 5.07% |
| 2022 FY | 36.94 Million USD | 55.09% |
| 2022 Q1 | 8.77 Million USD | 45.09% |
| 2022 Q4 | 10.32 Million USD | 19.78% |
| 2022 Q3 | 8.62 Million USD | -6.48% |
| 2021 Q3 | 6.14 Million USD | -0.86% |
| 2021 Q4 | 6.04 Million USD | -1.55% |
| 2021 Q1 | 6.5 Million USD | 0.74% |
| 2021 Q2 | 6.19 Million USD | -4.69% |
| 2021 FY | 23.82 Million USD | 10.35% |
| 2020 Q2 | 4.62 Million USD | -6.1% |
| 2020 Q3 | 5.62 Million USD | 21.68% |
| 2020 Q4 | 6.45 Million USD | 14.76% |
| 2020 FY | 21.58 Million USD | 13.09% |
| 2020 Q1 | 4.92 Million USD | 32.53% |
| 2019 Q1 | 3.6 Million USD | 26.53% |
| 2019 FY | 19.08 Million USD | 80.19% |
| 2019 Q2 | 5.15 Million USD | 43.04% |
| 2019 Q3 | 6.77 Million USD | 31.39% |
| 2019 Q4 | 3.71 Million USD | -45.21% |
| 2018 Q2 | 3.05 Million USD | -0.1% |
| 2018 FY | 10.59 Million USD | 1.17% |
| 2018 Q4 | 2.85 Million USD | 74.1% |
| 2018 Q3 | 1.63 Million USD | -46.36% |
| 2018 Q1 | 3.05 Million USD | 28.09% |
| 2017 Q2 | 3.91 Million USD | 15.53% |
| 2017 Q4 | 2.38 Million USD | 204.21% |
| 2017 Q1 | 3.38 Million USD | 44.85% |
| 2017 FY | 10.47 Million USD | -25.69% |
| 2017 Q3 | 784 Thousand USD | -79.97% |
| 2016 Q1 | 4.62 Million USD | 50.72% |
| 2016 FY | 14.09 Million USD | 31.67% |
| 2016 Q3 | 3.43 Million USD | -6.93% |
| 2016 Q4 | 2.33 Million USD | -31.93% |
| 2016 Q2 | 3.69 Million USD | -20.16% |
| 2015 Q3 | 2.57 Million USD | -4.57% |
| 2015 Q2 | 2.69 Million USD | 13.72% |
| 2015 Q1 | 2.36 Million USD | -19.56% |
| 2015 FY | 10.7 Million USD | -26.29% |
| 2015 Q4 | 3.06 Million USD | 19.33% |
| 2014 Q2 | 4.02 Million USD | 55.72% |
| 2014 Q3 | 4.94 Million USD | 22.82% |
| 2014 Q4 | 2.94 Million USD | -40.46% |
| 2014 FY | 14.51 Million USD | -5.17% |
| 2014 Q1 | 2.58 Million USD | -50.08% |
| 2013 Q3 | 2.33 Million USD | -63.68% |
| 2013 Q4 | 5.18 Million USD | 121.56% |
| 2013 Q2 | 6.43 Million USD | 375.13% |
| 2013 Q1 | 1.35 Million USD | 0.0% |
| 2013 FY | 15.31 Million USD | 226.6% |
| 2012 FY | 4.68 Million USD | 0.0% |
| 2009 Q1 | 3.48 Million USD | -27.01% |
| 2009 Q2 | 2.92 Million USD | -15.91% |
| 2009 Q3 | 2.86 Million USD | -2.05% |
| 2008 Q3 | 4.49 Million USD | -23.95% |
| 2008 FY | 21 Million USD | -15.09% |
| 2008 Q4 | 4.76 Million USD | 6.14% |
| 2008 Q1 | 5.83 Million USD | -17.55% |
| 2008 Q2 | 5.9 Million USD | 1.25% |
| 2007 Q1 | 35.24 Million USD | 524.41% |
| 2007 Q2 | 6.84 Million USD | -80.58% |
| 2007 Q3 | 5.56 Million USD | -18.66% |
| 2007 Q4 | 7.07 Million USD | 27.1% |
| 2007 FY | 24.73 Million USD | -44.52% |
| 2006 Q1 | 5.15 Million USD | -5.82% |
| 2006 Q2 | 28.97 Million USD | 461.73% |
| 2006 Q4 | 5.64 Million USD | 17.36% |
| 2006 Q3 | 4.81 Million USD | -83.4% |
| 2006 FY | 44.58 Million USD | 81.9% |
| 2005 Q2 | 6.46 Million USD | 0.68% |
| 2005 FY | 24.51 Million USD | 2.4% |
| 2005 Q3 | 6.14 Million USD | -5.02% |
| 2005 Q1 | 6.42 Million USD | 20.91% |
| 2005 Q4 | 5.47 Million USD | -10.84% |
| 2004 Q3 | 5.74 Million USD | -16.68% |
| 2004 Q4 | 5.31 Million USD | -7.5% |
| 2004 Q1 | 5.98 Million USD | 0.39% |
| 2004 Q2 | 6.89 Million USD | 15.15% |
| 2004 FY | 23.93 Million USD | 5.51% |
| 2003 Q2 | 5.76 Million USD | -1.92% |
| 2003 Q4 | 5.96 Million USD | 17.4% |
| 2003 FY | 22.68 Million USD | -42.92% |
| 2003 Q1 | 5.87 Million USD | -26.1% |
| 2003 Q3 | 5.08 Million USD | -11.88% |
| 2002 FY | 39.74 Million USD | -16.29% |
| 2002 Q1 | 11.59 Million USD | -27.82% |
| 2002 Q2 | 10.86 Million USD | -6.31% |
| 2002 Q3 | 9.33 Million USD | -14.09% |
| 2002 Q4 | 7.95 Million USD | -14.78% |
| 2001 Q3 | -6.34 Million USD | -166.13% |
| 2001 Q4 | 16.06 Million USD | 353.13% |
| 2001 Q2 | 9.59 Million USD | -3.43% |
| 2001 Q1 | 9.93 Million USD | -10.35% |
| 2001 FY | 47.48 Million USD | 66.73% |
| 2000 Q3 | 6.2 Million USD | 3.37% |
| 2000 FY | 28.47 Million USD | 46.05% |
| 2000 Q4 | 11.08 Million USD | 78.51% |
| 2000 Q2 | 6 Million USD | 16.03% |
| 2000 Q1 | 5.17 Million USD | 107.1% |
| 1999 FY | 19.5 Million USD | 8.94% |
| 1999 Q1 | 4.4 Million USD | -25.42% |
| 1999 Q2 | 4.5 Million USD | 2.27% |
| 1999 Q3 | 5 Million USD | 11.11% |
| 1999 Q4 | 2.5 Million USD | -50.0% |
| 1998 Q2 | 3.8 Million USD | -13.64% |
| 1998 Q4 | 5.9 Million USD | 51.28% |
| 1998 Q3 | 3.9 Million USD | 2.63% |
| 1998 Q1 | 4.4 Million USD | -24.14% |
| 1998 FY | 17.9 Million USD | 2.87% |
| 1997 Q3 | 3.8 Million USD | -2.56% |
| 1997 Q1 | 3.9 Million USD | -33.9% |
| 1997 FY | 17.4 Million USD | 6.75% |
| 1997 Q4 | 5.8 Million USD | 52.63% |
| 1997 Q2 | 3.9 Million USD | 0.0% |
| 1996 FY | 16.3 Million USD | 36.97% |
| 1996 Q4 | 5.9 Million USD | 34.09% |
| 1996 Q3 | 4.4 Million USD | 46.67% |
| 1996 Q1 | 3 Million USD | -30.23% |
| 1996 Q2 | 3 Million USD | 0.0% |
| 1995 Q3 | 2.3 Million USD | -8.0% |
| 1995 Q4 | 4.3 Million USD | 86.96% |
| 1995 FY | 11.9 Million USD | 19.0% |
| 1995 Q1 | 2.7 Million USD | -25.0% |
| 1995 Q2 | 2.5 Million USD | -7.41% |
| 1994 Q4 | 3.6 Million USD | 50.0% |
| 1994 FY | 10 Million USD | 69.49% |
| 1994 Q1 | - USD | 100.0% |
| 1994 Q2 | 2.2 Million USD | 0.0% |
| 1994 Q3 | 2.4 Million USD | 9.09% |
| 1993 Q4 | -5.5 Million USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 FY | 5.9 Million USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | 63.683% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -25.691% |
| Actinium Pharmaceuticals, Inc. | 52 Million USD | 77.599% |
| Azitra, Inc. | 8.3 Million USD | -40.309% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -30.331% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -69.754% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | 59.82% |
| CEL-SCI Corporation | 31.47 Million USD | 62.991% |
| iBio, Inc. | 16.85 Million USD | 30.903% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | 64.707% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | 42.281% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | 53.145% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 16.384% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | 9.684% |
| NanoViricides, Inc. | 8.51 Million USD | -36.788% |
| Oragenics, Inc. | 5.45 Million USD | -113.667% |
| BiomX Inc. | 26.81 Million USD | 56.556% |
| BiomX Inc. | 26.81 Million USD | 56.556% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | 63.656% |
| Palatin Technologies, Inc. | 34.67 Million USD | 66.401% |
| Scorpius Holdings, Inc. | 39.81 Million USD | 70.743% |